Seprafilm
ADHESION BARRIER

Preparation and Application Techniques

SEPRAFILM Full Sheet Application

The "Taco" Technique



Expose edge of SEPRAFILM (1-2 cm)



Allow exposed SEPRAFILM to adhere to desired tissue



Withdraw holder

The "Quilting" Technique

Cut SEPRAFILM and holder with scissors



Remove from holder and apply



May be curved to facilitate entry

SEPRAFILM 4-Section Application

Open protective envelope



Slide product out

Apply, overlap and tap

Handling Tips

SEPRAFILM can be:

Cut to any shape or size



Curved or rolled



Molded to desired contour



Packaging notch facilitates exchange in the OR **(SEPRAILM 4-Section ONLY)**

General Considerations & Directions for Use

- Keep SEPRAFILM, gloves, instruments and site of application dry.
- Keep a dry lap on the field to dry off wet gloves and instruments before handling SEPRAFILM.
- Use standard irrigation solution if contact occurs with unintended tissue surface.
- You may choose to place SEPRAFILM with dry instruments, the product covering, dry gloved hand, or any combination of the above.

Please see Indication and Detailed Important Risk Information on the reverse side.

Baxter

Indications

Seprafilm is intended as an adjunct in abdominal and pelvic surgery for reducing the incidence, extent and severity of postoperative adhesions at the site of placement, and to reduce adhesive small bowel obstruction when placed in the abdomen.

Important Risk Information

Seprafilm should not be wrapped directly around a fresh anastomotic suture or staple line of the intestine. Clinical trial data on Seprafilm indicate that such use may result in an increased risk of anastomotic leak-related events (fistula, abscess, leak, sepsis and peritonitis). The incidence of these events was not affected when Seprafilm was placed elsewhere in the abdomen.

Seprafilm is not recommended for use in women undergoing surgery for ovarian, fallopian tube or peritoneal malignancies. Some clinical literature has associated this use of Seprafilm with an increased incidence of fluid collection and/or abscess requiring intervention.

No controlled clinical studies have been conducted in patients with active infections or abdominopelvic malignancy.

Foreign body reaction may occur as with most surgical adjuncts but have been rarely reported during clinical use.

No pre-clinical reproductive studies have been conducted. No clinical studies have been conducted in women who become pregnant in the first month after application of Seprafilm. Therefore, avoiding pregnancy during the first complete menstrual cycle after the use of Seprafilm should be considered.

Ordering Information

Item Number	430102	638001	664201	508602
Configuration	Seprafilm Adhesion Barrier	Seprafilm 4-Section	Seprafilm Small Incision	Seprafilm Procedure Pack
Pouch Contents	 1 full sheet	 4 quarter sheets	 2 half sheets	 6 half sheets
Individual Sheet Size	1 (5" x 6") sheet /pouch	4 (3" x 2.5") sheets /pouch	2 (3" x 5") sheets /pouch	6 (3" x 5") sheets /pouch
Packaging	10 pouches/box	10 pouches/box	10 pouches/box	5 pouches/box

For questions or ordering information, please contact your Baxter representative.

Advancing the art of healing

USA
Baxter Healthcare Corporation
1 Baxter Parkway
Deerfield, IL 60015

Baxter, Advancing the Art of Healing, and Seprafilm are trademarks of Baxter International Inc.
GLBL/SEP/20-0004 02/2020

CE 2797

Baxter